As cases of COVID-19, flu and RSV tick up, amid a scarcity of OTC children’s pain relief products at certain locations, retailers have begun to institute product limits.
Tzield is the first and only treatment indicated to delay the onset of stage 3 type 1 diabetes in adult and pediatric patients aged 8 years old and older with stage 2 type 1 diabetes.
Fresenius Kabi's lacosamide injection for intravenous use is indicated for the treatment of partial-onset seizures in patients aged 17 years old and older.
Over-the-counter hearing aids, personal sound amplifiers and hearing protection will be available in 52 of the retailer's stores in New York and Vermont.
For the third quarter, Rite Aid reported a net loss of $67.1 million, or $1.23 loss per share, adjusted net loss of $7.9 million, or 14 cents loss per share.